Posted
Bristol-Myers Squibb has taken a step toward closing its deal for Celgene with the $13 bln sale of the latter’s psoriasis drug to Amgen. Richard Beales says the rich price lends credence to Bristol-Myers’ claim that Celgene was undervalued, and deserving of its $74 bln offer.
02:00
01:51
01:52
01:51
02:03
02:12
01:46
00:55
01:30
01:45
01:27
01:55
05:34
03:15
02:05
02:13
01:08
02:06
01:01
01:12
00:37
01:11
00:41
00:39
02:30
01:16
01:41
02:00
00:58
00:41
01:08
01:35
01:09
00:40
01:33
01:16
00:35
01:08
02:25
01:16
01:19
01:58
01:12
00:35
01:48
02:57
01:36
02:00
01:25
02:44
00:48
01:18
00:45
02:49
02:16